Title21 names new CEO and president after cResults acquisition

Title21 Health Solutions appointed Rafi Maslaton as CEO and Jonathan Wofford as president as part of its post-acquisition integration plan following the purchase of cResults. The changes are meant to strengthen the company’s push into AI-enabled healthcare technology for regulated life sciences and healthcare markets.

Why it matters: - Title21 is reorganizing leadership to support its next phase of growth after acquiring cResults. - The company is aiming to expand beyond compliance software into a more AI-enabled digital healthcare platform. - The move matters for healthcare and life sciences customers that want software for regulated operations, automation and data-driven decision-making.

What happened: - Title21 Health Solutions named Rafi Maslaton chief executive officer, while he keeps his role as chief technical officer. - Jonathan Wofford was appointed president and will remain chief commercial officer. - The company announced the changes on Aug. 19, 2026, in Phoenix. - Title21 said the leadership transition is part of the integration plan following its acquisition of cResults.

The details: - Maslaton will oversee corporate, product and technology strategy. - Title21 said Maslaton will focus on accelerating the company’s move toward a compliant, AI-enabled digital healthcare platform for regulated environments. - Wofford will direct commercial strategy and execution. - Title21 said Wofford’s role is to align customer needs and market opportunities with the company’s technology portfolio. - Maslaton has more than 30 years of experience in operations, manufacturing engineering, information systems, technology development and business management in regulated industries. - As president and founder of cResults, Maslaton led development of the Smart-QX platform, including Smart-QC, Smart-QA, Smart-AId and Smart-FDA. - Maslaton previously served as chief operating officer at Sparta Systems, which supported more than 100 FDA-regulated organizations, including major life sciences companies. - Maslaton also was a senior partner at Tefen, where he oversaw the pharmaceutical and biotechnology sectors. - Wofford joined Title21 as chief commercial officer in 2025. - Wofford brings more than 20 years of experience in cell therapy, blood and marrow transplantation, clinical research, healthcare technology and the cell and gene therapy supply chain. - Title21 said the leadership shift comes as the company expands capabilities in cell and gene therapy, manufacturing, quality management, planning and scheduling, digital documentation, compliance intelligence and advanced analytics. - The cResults integration adds intelligent resource planning, automation, operational performance management and AI-enabled capabilities.

Between the lines: - The executive changes signal a tighter link between product development and commercial execution. - Title21 is pairing domain expertise in regulated healthcare with a stronger AI and automation message. - Maslaton’s background suggests the company wants technical leadership that can bridge compliance requirements and product innovation. - Wofford’s commercial role points to a focus on converting technical expansion into customer adoption.

What's next: - Title21 is expected to keep building products for healthcare and life sciences organizations operating in regulated environments. - The company said its next-generation platform will turn data into intelligence and intelligence into action. - Future growth will likely depend on how well Title21 integrates cResults and delivers measurable operational gains for customers.

The bottom line: - Title21 is using a post-acquisition leadership reset to push deeper into AI-enabled healthcare software while keeping compliance at the center of its pitch.